Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 108

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 108
---
684

    17,556

    Commitments and contingencies (Note 9)

    Stockholders’ equity

    Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized,no shares issued and outstanding as of December 31, 2024 and 2023

    —

    —

    Common stock, par value of $0.001 per share; 300,000,000 shares authorized at December 31, 2024 and December 31, 2023; 65,880,914 shares issued and outstanding as of December 31, 2024 and December 31, 2023

    66

    66

    Additional paid-in capital

    413,113

    406,587

    Accumulated deficit

    (359,313
    )

    (263,822
    )

    Accumulated other comprehensive loss

    (6,851
    )

    (9,669
    )

    Total stockholders’ equity

    47,015

    133,162

    Total liabilities and stockholders’ equity
     
    $
    67,699

    $
    150,718

See accompanying notes to the consolidated financial statements. 

143

io biotech, inc 

Consolidated Statements of Operations and Comprehensive Loss 

(In thousands, except share and per share amounts) 

    Year Ended December 31,

    2024

    2023

    Operating expenses

    Research and development
     
    $
    71,484

    $
    67,829

    General and administrative

    23,693

    23,614

    Total operating expenses

    95,177

    91,443

    Loss from operations

    (95,177
    )

    (91,443
    )

    Other income (expense)

    Currency exchange (loss) gain, net

    (3,589
    )

    331

    Interest income

    4,718

    5,881

    Total other income, net

    1,129

    6,212

    Loss before income tax expense

    (94,048
    )

    (85,231
    )

    Income tax expense

    1,443

    852

    Net loss

    (95,491
    )

    (